Kura Oncology https://validator.w3.org/feed/docs/rss2.html Careers Tom Doyle Home Patients and Caregivers Media Resources Newsroom Pipeline Access To Investigational Drugs Outside a Clinical Study Kura Oncology Named 2025 Fierce 50 Honoree Kura CMO Mollie Leoni Featured as <em>In Vivo</em> 2025 Rising Leader 2025 Scrip Awards Deal of the Year Finalist SDUT San Diego Top Workplaces 2024 Komzifti Footer Terms of Use Posters and Presentations Head & Neck Acute Leukemias Compliance Declaration Contact Consumer Health Data Cookie Policy Investigator Sponsored Studies AML World Awareness Day and Kura’s Commitment Privacy Policy Grants & Funding Progress By Collaboration: The Development of Kura’s Menin Inhibitor for AML Research Scrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends Mary Szela Thank You, From Kura Oncology Carol Schafer Samir Vattompadam Troy Wilson, Ph.D., J.D. Diane Parks Thomas Malley Helen Collins, M.D. Faheem Hasnain Troy Wilson, Ph.D., J.D. PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials Our Approach The Story Behind Our Name Asking the Right Questions in R&D Kura CEO Troy Wilson Named an EY Entrepreneur Of The Year<sup>®</sup> 2025 Pacific Southwest Award Winner Roger Bakale, Ph.D. Achievement in Operational Excellence to Deliver Business Transformation Brian Powl Pipeline v3 Michael Vasconcelles, M.D. Mollie Leoni, M.D. About Us